SS-31 Elamipretide is a prescription therapy used for mitochondrial support.

Patients seeking support for mitochondrial support may qualify after evaluation by a licensed provider.

Yes. SS-31 Elamipretide is a compounded peptide that requires a valid prescription from a licensed provider. A telehealth consultation and medical intake are required before dispensing to ensure SS-31 is appropriate for your health history, goals, and current medications.

Injection site reactions including transient redness, mild swelling, or discomfort are the most commonly reported effects with subcutaneous administration. Some patients report mild fatigue or headache during initial dosing, which typically resolves as the body adjusts. Transient nausea has been noted in a small number of patients, particularly following initial doses. As with any peptide therapy, individual responses vary. Report any unusual or persistent symptoms to your provider.

SS-31 Elamipretide is not appropriate for patients who are pregnant or breastfeeding, as safety data in these populations is insufficient. Patients with a history of active malignancy should not use SS-31 without thorough oncological and provider evaluation. Those with severe cardiac, hepatic, or renal impairment require individualized provider review before starting, as these conditions may affect peptide metabolism, clearance, and mitochondrial response. SS-31 has not been studied in pediatric populations and is not indicated for patients under 18. Disclose your full medical history, current medications, and any history of malignancy before starting treatment.

Because SS-31 improves mitochondrial energy efficiency and reduces oxidative stress, patients on cardioprotective medications including beta-blockers, ACE inhibitors, or statins should disclose concomitant use with their provider, as effects on cardiac energy metabolism may be additive. Patients on antioxidant therapy including CoQ10, NAD+ precursors, or alpha-lipoic acid should discuss concurrent use, as overlapping mechanisms may alter dosing requirements. Those on immunomodulatory or anti-inflammatory agents should exercise caution given SS-31's influence on ROS signaling and mitochondrial membrane dynamics. Always provide a complete medication list to your provider before beginning treatment.

Patients with a history of any malignancy should not use SS-31 without thorough oncological and provider evaluation. Those with heart failure, cardiomyopathy, or ischemic heart disease may be candidates for SS-31 given its cardioprotective mitochondrial mechanisms, but require close provider supervision and individualized dosing. Patients with chronic kidney disease should disclose their full renal history, as SS-31 has been investigated in renal ischemia models and may influence kidney energy metabolism in ways that require monitoring. Those with neurodegenerative conditions, metabolic syndrome, or significant oxidative stress-related disease require careful provider review before starting. Your provider requires a complete medical history before prescribing and will determine whether SS-31 is appropriate given your individual health profile.